Allon Therapeutics
Posted: Tue May 02, 2006 2:46 pm
They say they plan to initiate phase II trials in 2006, and that there will be multiple trials, so I hope they include MS...
Allon Therapeutics Presents CSF and Bioavailability Data at IBC's TIDES 2006
CCNMatthews - May 2, 2006 - Allon Therapeutics Inc. has presented a case study during IBC's "TIDES 2006: Oligonucleotide and Peptide Technology and Product Development" in Carlsbad, California.
This pre-clinical study confirmed that Allon's drug candidates penetrate the blood brain barrier, have a well-understood bioavailability and reach their target therapeutic areas in the central nervous system. It also showed that the intranasal administration of AL-108 and the intravenous administration of AL-208 appeared rapidly in the plasma, cerebrospinal fluid and the brain.
The presentation, entitled "NAP: Drug Development of a Neuroprotective Peptide", was given by Dr. Bruce Morimoto, Vice President, Drug Development of Allon Therapeutics Inc. on May 1, 2006. He discussed the quantitative whole body autoradiography results and specifically, the pharmacokinetics of AL-108 and AL-208 in the cerebrospinal fluid and brain.
AL-108 and AL-208 are eight amino acid neuropeptides that have shown preclinical efficacy in a number of neurodegenerative models. AL-108 is Allon's intranasal neuroprotective product, currently in Phase I human clinical trials for the treatment of Alzheimer's disease. AL-208 is an intravenous product that completed Phase I testing for the prevention of mild cognitive impairment associated with post-coronary artery bypass graft surgery. Allon expects both of these products will enter Phase II clinical trials in 2006.
"The findings of this study are important because it shows Allon's products have formulations and routes of administration that address both acute and chronic neurodegenerative conditions," said Morimoto. "This broad applicability allows Allon to pursue multiple Phase II clinical trials in indications requiring either nasal or intravenous administration."
The peptide study was carried out by Montreal-based Charles River Canada, part of Charles River Laboratories Inc. (NYSE:CRL), a leading contract research organization for drug development services.
About Allon
Allon Therapeutics Inc. is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer's disease, mild cognitive impairment, stroke, traumatic brain injury, multiple sclerosis and neuropathy. The company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company) and based in Vancouver.
http://www.ccnmatthews.com/news/release ... For=592431
Allon Therapeutics Presents CSF and Bioavailability Data at IBC's TIDES 2006
CCNMatthews - May 2, 2006 - Allon Therapeutics Inc. has presented a case study during IBC's "TIDES 2006: Oligonucleotide and Peptide Technology and Product Development" in Carlsbad, California.
This pre-clinical study confirmed that Allon's drug candidates penetrate the blood brain barrier, have a well-understood bioavailability and reach their target therapeutic areas in the central nervous system. It also showed that the intranasal administration of AL-108 and the intravenous administration of AL-208 appeared rapidly in the plasma, cerebrospinal fluid and the brain.
The presentation, entitled "NAP: Drug Development of a Neuroprotective Peptide", was given by Dr. Bruce Morimoto, Vice President, Drug Development of Allon Therapeutics Inc. on May 1, 2006. He discussed the quantitative whole body autoradiography results and specifically, the pharmacokinetics of AL-108 and AL-208 in the cerebrospinal fluid and brain.
AL-108 and AL-208 are eight amino acid neuropeptides that have shown preclinical efficacy in a number of neurodegenerative models. AL-108 is Allon's intranasal neuroprotective product, currently in Phase I human clinical trials for the treatment of Alzheimer's disease. AL-208 is an intravenous product that completed Phase I testing for the prevention of mild cognitive impairment associated with post-coronary artery bypass graft surgery. Allon expects both of these products will enter Phase II clinical trials in 2006.
"The findings of this study are important because it shows Allon's products have formulations and routes of administration that address both acute and chronic neurodegenerative conditions," said Morimoto. "This broad applicability allows Allon to pursue multiple Phase II clinical trials in indications requiring either nasal or intravenous administration."
The peptide study was carried out by Montreal-based Charles River Canada, part of Charles River Laboratories Inc. (NYSE:CRL), a leading contract research organization for drug development services.
About Allon
Allon Therapeutics Inc. is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer's disease, mild cognitive impairment, stroke, traumatic brain injury, multiple sclerosis and neuropathy. The company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company) and based in Vancouver.
http://www.ccnmatthews.com/news/release ... For=592431